Top 5 Most-Watched Video Interviews of 2025

The top 5 most-viewed videos of 2025 explored a range of topics, including data presented at major medical meetings, health care policy developments, and infectious disease concerns.

Here are AJMC.com’s 5 most-viewed videos of 2025. View all interview clips from The American Journal of Managed Care® (AJMC®) here.

This year's most-watched video evaluated how President Donald Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives. | Image Credit: LIGHTFIELD STUDIOS - stock.adobe.com

5. Phase 3 POLARGO Trial Shows Survival Benefit of Polatuzumab-Based Regimen in R/R DLBCL: Matthew Matasar, MD

Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma, Matthew Matasar, MD, of Rutgers Cancer Institute, shared in an on-site interview at the 2025 European Hematology Association Congress in Milan, Italy. He noted that polatuzumab was originally approved for this population in combination with bendamustine and rituximab. However, investigators have since learned that bendamustine can be harmful in this setting and may limit the effectiveness of subsequent treatments, including chimeric antigen receptor T-cell therapy.

Watch the full video.

4. Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed

Histotripsy is a novel technique that uses high-frequency ultrasound waves to destroy tumors and is currently approved only for the treatment of liver cancer. However, the approach is also being explored in other solid tumors, including kidney, prostate, and pancreas cancers, Shaun P. McKenzie, MD, FACS, of Texas Oncology, shared in this interview clip from February. He added that histotripsy was first studied in the liver because it is a durable organ and the site with the greatest experience in ablative therapy.

Watch the full video.

3. CROI to Present New Insights on Long COVID Risk, HIV Cure

In an interview ahead of this year’s Conference on Retroviruses and Opportunistic Infections, held in San Francisco from March 9 to 12, Annie Antar, MD, PhD, of Johns Hopkins Medicine, previewed findings she was presenting at the meeting from 2 large studies on long COVID: Test Us at Home and Test Us at Home Daily. She explained that slower viral clearance was strongly associated with the development of long COVID and that a higher symptom burden was linked to slower clearance. Antar also highlighted a potential association between viral rebound and increased long COVID risk.

Watch the full video.

2. Kansas City Tuberculosis Outbreak: A Deadly Wake-Up Call

Earlier this year, a tuberculosis (TB) outbreak in the Kansas City metro area resulted in dozens of cases and at least 2 deaths. Amid the ongoing outbreak, Michael A. Bernstein, MD, director of pulmonary and critical care at Stamford Health, addressed common TB misconceptions in a February interview with AJMC. Although many people assume TB is rare and no longer a concern in 2025, he noted that it remains relatively common. Although the Kansas City outbreak itself is not surprising to most pulmonologists, Bernstein explained that the deaths are more unexpected, as TB is generally not highly fatal given available treatment options; this makes the outbreak somewhat unique.

Watch the full video.

1. How Trump’s Initial Executive Orders May Impact Medicaid, Medicare Models

Published just 10 days after President Donald Trump took office, this year’s top video featured Adam Colborn, JD, of the Academy of Managed Care Pharmacy, who discussed how the rescission of several Biden-era executive orders may impact efforts to reform the US health care system. He noted that the rescinded orders primarily affect Medicare and Medicaid, creating uncertainty around several Center for Medicare and Medicaid Innovation models, including the Part D $2 Drug List, and leaving their implementation status unclear. However, Colborn explained that many Medicaid-related initiatives had already achieved their intended goals. Looking ahead, he hypothesized that additional drug pricing and related reforms are likely to come from Congress.

Watch the full video.